Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Implications of Social Groups on Sedentary Behavior of Children with Autism: A Pilot Study.

Schenkelberg MA, Rosenkranz RR, Milliken GA, Menear K, Dzewaltowski DA.

J Autism Dev Disord. 2017 Apr;47(4):1223-1230. doi: 10.1007/s10803-017-3037-0.

PMID:
28181052
2.

Exercise following Mental Work Prevented Overeating.

Neumeier WH, Goodner E, Biasini F, Dhurandhar EJ, Menear KS, Turan B, Hunter GR.

Med Sci Sports Exerc. 2016 Sep;48(9):1803-9. doi: 10.1249/MSS.0000000000000961.

3.

Obesity, Physical Activity and Sedentary Behaviors in Children with an Autism Spectrum Disorder.

Corvey K, Menear KS, Preskitt J, Goldfarb S, Menachemi N.

Matern Child Health J. 2016 Feb;20(2):466-76. doi: 10.1007/s10995-015-1844-5.

PMID:
26515467
4.

Wellness among US adolescents ages 12-17 years.

Preskitt JK, Menear KS, Goldfarb SS, Menachemi N.

Child Care Health Dev. 2015 Nov;41(6):1207-15. doi: 10.1111/cch.12248. Epub 2015 Apr 5.

PMID:
25846725
5.

Correlates of wellness among youth with functional disabilities.

Menear KS, Preskitt JK, Goldfarb SS, Menachemi N.

Disabil Health J. 2015 Apr;8(2):223-30. doi: 10.1016/j.dhjo.2014.10.001. Epub 2014 Oct 17.

PMID:
25457291
6.

Physical activity and physical fitness of school-aged children and youth with autism spectrum disorders.

Tyler K, MacDonald M, Menear K.

Autism Res Treat. 2014;2014:312163. doi: 10.1155/2014/312163. Epub 2014 Sep 16.

7.

1-substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones endowed with dual DNA-PK/PI3-K inhibitory activity.

Cano C, Saravanan K, Bailey C, Bardos J, Curtin NJ, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Menear KA, Newell DR, Richardson CJ, Shea K, Smith GC, Thommes P, Ting A, Griffin RJ.

J Med Chem. 2013 Aug 22;56(16):6386-401. doi: 10.1021/jm400915j. Epub 2013 Aug 1.

PMID:
23855836
8.

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014.

Pike KG, Malagu K, Hummersone MG, Menear KA, Duggan HM, Gomez S, Martin NM, Ruston L, Pass SL, Pass M.

Bioorg Med Chem Lett. 2013 Mar 1;23(5):1212-6. doi: 10.1016/j.bmcl.2013.01.019. Epub 2013 Jan 18.

PMID:
23375793
9.

Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K.

Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, Tavecchio M, Barbeau J, Bardos J, Cornell L, Griffin RJ, Menear K, Slade A, Thommes P, Martin NM, Newell DR, Smith GC, Curtin NJ.

Mol Cancer Ther. 2012 Aug;11(8):1789-98. doi: 10.1158/1535-7163.MCT-11-0535. Epub 2012 May 10.

10.

DNA-dependent protein kinase (DNA-PK) inhibitors: structure-activity relationships for O-alkoxyphenylchromen-4-one probes of the ATP-binding domain.

Clapham KM, Bardos J, Finlay MR, Golding BT, Griffen EJ, Griffin RJ, Hardcastle IR, Menear KA, Ting A, Turner P, Young GL, Cano C.

Bioorg Med Chem Lett. 2011 Feb 1;21(3):966-70. doi: 10.1016/j.bmcl.2010.12.047. Epub 2010 Dec 13.

PMID:
21216595
11.

DNA-dependent protein kinase (DNA-PK) inhibitors. Synthesis and biological activity of quinolin-4-one and pyridopyrimidin-4-one surrogates for the chromen-4-one chemotype.

Cano C, Barbeau OR, Bailey C, Cockcroft XL, Curtin NJ, Duggan H, Frigerio M, Golding BT, Hardcastle IR, Hummersone MG, Knights C, Menear KA, Newell DR, Richardson CJ, Smith GC, Spittle B, Griffin RJ.

J Med Chem. 2010 Dec 23;53(24):8498-507. doi: 10.1021/jm100608j. Epub 2010 Nov 16.

PMID:
21080722
12.

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, Critchlow SE, Vincent JP, Ellston R, Jones D, Sini P, James D, Howard Z, Dudley P, Hughes G, Smith L, Maguire S, Hummersone M, Malagu K, Menear K, Jenkins R, Jacobsen M, Smith GC, Guichard S, Pass M.

Cancer Res. 2010 Jan 1;70(1):288-98. doi: 10.1158/0008-5472.CAN-09-1751. Epub 2009 Dec 22.

13.

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion.

Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, Chong WY, Hummersone M, Rigoreau L, Menear KA, O'Connor MJ, Povirk LF, van Meter T, Valerie K.

Mol Cancer Ther. 2009 Oct;8(10):2894-902. doi: 10.1158/1535-7163.MCT-09-0519. Epub 2009 Oct 6.

14.

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase.

Malagu K, Duggan H, Menear K, Hummersone M, Gomez S, Bailey C, Edwards P, Drzewiecki J, Leroux F, Quesada MJ, Hermann G, Maine S, Molyneaux CA, Le Gall A, Pullen J, Hickson I, Smith L, Maguire S, Martin N, Smith G, Pass M.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5950-3. doi: 10.1016/j.bmcl.2009.08.038. Epub 2009 Aug 13.

PMID:
19762236
15.

Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR.

Menear KA, Gomez S, Malagu K, Bailey C, Blackburn K, Cockcroft XL, Ewen S, Fundo A, Le Gall A, Hermann G, Sebastian L, Sunose M, Presnot T, Torode E, Hickson I, Martin NM, Smith GC, Pike KG.

Bioorg Med Chem Lett. 2009 Oct 15;19(20):5898-901. doi: 10.1016/j.bmcl.2009.08.069. Epub 2009 Aug 21.

PMID:
19733066
16.

The P1N-isopropyl motif bearing hydroxyethylene dipeptide isostere analogues of aliskiren are in vitro potent inhibitors of the human aspartyl protease renin.

Yamaguchi Y, Menear K, Cohen NC, Mah R, Cumin F, Schnell C, Wood JM, Maibaum J.

Bioorg Med Chem Lett. 2009 Aug 15;19(16):4863-7. doi: 10.1016/j.bmcl.2009.05.128. Epub 2009 Jun 26.

PMID:
19615901
17.

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.

Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, Dillon KJ, Drzewiecki J, Garman S, Gomez S, Javaid H, Kerrigan F, Knights C, Lau A, Loh VM Jr, Matthews IT, Moore S, O'Connor MJ, Smith GC, Martin NM.

J Med Chem. 2008 Oct 23;51(20):6581-91. doi: 10.1021/jm8001263. Epub 2008 Sep 19.

PMID:
18800822
18.

8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK).

Desage-El Murr M, Cano C, Golding BT, Hardcastle IR, Hummersome M, Frigerio M, Curtin NJ, Menear K, Richardson C, Smith GC, Griffin RJ.

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4885-90. doi: 10.1016/j.bmcl.2008.07.066. Epub 2008 Jul 20.

PMID:
18678488
19.

Novel alkoxybenzamide inhibitors of poly(ADP-ribose) polymerase.

Menear KA, Adcock C, Alonso FC, Blackburn K, Copsey L, Drzewiecki J, Fundo A, Le Gall A, Gomez S, Javaid H, Lence CF, Martin NM, Mydlowski C, Smith GC.

Bioorg Med Chem Lett. 2008 Jul 15;18(14):3942-5. doi: 10.1016/j.bmcl.2008.06.025. Epub 2008 Jun 12.

PMID:
18579376
20.

Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase.

Hollick JJ, Rigoreau LJ, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, Golding BT, Guiard S, Hardcastle IR, Hickson I, Hummersone MG, Menear KA, Martin NM, Matthews I, Newell DR, Ord R, Richardson CJ, Smith GC, Griffin RJ.

J Med Chem. 2007 Apr 19;50(8):1958-72. Epub 2007 Mar 20.

PMID:
17371003
21.

Physiological responses of skilled players during a competitive wheelchair tennis match.

Roy JL, Menear KS, Schmid MM, Hunter GR, Malone LA.

J Strength Cond Res. 2006 Aug;20(3):665-71.

PMID:
16977715
22.

Phthalazinones 2: Optimisation and synthesis of novel potent inhibitors of poly(ADP-ribose)polymerase.

Cockcroft XL, Dillon KJ, Dixon L, Drzewiecki J, Kerrigan F, Loh VM Jr, Martin NM, Menear KA, Smith GC.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):1040-4. Epub 2005 Nov 15.

PMID:
16290932
23.

Direct thrombin inhibitors: current status and future prospects.

Menear K.

Expert Opin Investig Drugs. 1999 Sep;8(9):1373-84.

PMID:
15992155
24.

Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP-ribose)polymerase.

Loh VM Jr, Cockcroft XL, Dillon KJ, Dixon L, Drzewiecki J, Eversley PJ, Gomez S, Hoare J, Kerrigan F, Matthews IT, Menear KA, Martin NM, Newton RF, Paul J, Smith GC, Vile J, Whittle AJ.

Bioorg Med Chem Lett. 2005 May 2;15(9):2235-8.

PMID:
15837300
25.

Syk-deficient eosinophils show normal interleukin-5-mediated differentiation, maturation, and survival but no longer respond to FcgammaR activation.

Lach-Trifilieff E, Menear K, Schweighoffer E, Tybulewicz VL, Walker C.

Blood. 2000 Oct 1;96(7):2506-10.

PMID:
11001904
26.

The design and synthesis of thrombin inhibitors: the introduction of in vivo efficacy and oral bioavailability into benzthiazolylalanine inhibitors.

Hayler J, Kane PD, LeGrand D, Lugrin F, Menear K, Price R, Allen M, Cockcroft X, Ambler J, Butler K, Dunnet K, Mitchelson A, Talbot M, Tweed M, Wills N.

Bioorg Med Chem Lett. 2000 Jul 17;10(14):1567-70.

PMID:
10915052
27.

Purification and characterization of human Syk produced using a baculovirus expression system.

Baldock D, Graham B, Akhlaq M, Graff P, Jones CE, Menear K.

Protein Expr Purif. 2000 Feb;18(1):86-94.

PMID:
10648173
28.

Optimisation of the P2 pharmacophore in a series of thrombin inhibitors: ion-dipole interactions with lysine 60G.

Ambler J, Brown L, Cockcroft XL, Gr├╝tter M, Hayler J, Janus D, Jones D, Kane P, Menear K, Priestle J, Smith G, Talbot M, Walker CV, Wathey B.

Bioorg Med Chem Lett. 1999 May 3;9(9):1317-22.

PMID:
10340621
29.

The discovery of orally available thrombin inhibitors: optimisation of the P1 pharmacophore.

Ambler J, Bentley D, Brown L, Dunnet K, Farr D, Janus D, Le Grand D, Menear K, Mercer M, Talbot M, Tweed M, Wathey B.

Bioorg Med Chem Lett. 1999 Apr 19;9(8):1103-8.

PMID:
10328293
30.

Studies towards the identification of potent, selective and bioavailable thrombin inhibitors.

Ambler J, Baker E, Bentley D, Brown L, Butler K, Butler P, Farr D, Dunnet K, Le Grand D, Hayler J, Janus D, Jones D, Menear K, Mercer M, Smith G, Talbot M, Tweed M.

Bioorg Med Chem Lett. 1999 Mar 8;9(5):737-42.

PMID:
10201839
31.

The discovery of orally available thrombin inhibitors: studies towards the optimisation of CGH1668.

Ambler J, Baker E, Brown L, Butler P, Farr D, Dunnet K, Le Grand D, Janus D, Jones D, Menear K, Mercer M, Smith G, Talbot M, Tweed M.

Bioorg Med Chem Lett. 1998 Dec 15;8(24):3583-8.

PMID:
9934475
32.

Progress towards the discovery of orally active thrombin inhibitors.

Menear K.

Curr Med Chem. 1998 Dec;5(6):457-68. Review.

PMID:
9873110
33.

Studies on the uptake of low molecular weight monomeric tris-galactosyl conjugates by the rat liver.

Eichler HG, Menear KA, Dunnet KE, Hastewell JG, Taylor PW.

Biochem Pharmacol. 1992 Dec 1;44(11):2117-22.

PMID:
1472076
34.

Hypolipidaemic activity of a novel acyclic ansamycin derivative. Synthesis and pharmacokinetic and pharmacodynamic studies in rodents.

Menear KA, Dunnet KE, Hastewell JG, Eichler HG, Gibson JC, Kimble EF, Kump W, Taylor PW.

Arzneimittelforschung. 1992 Sep;42(9):1125-9.

PMID:
1445480

Supplemental Content

Loading ...
Support Center